Mirum Pharmaceuticals, Inc. MIRM
We take great care to ensure that the data presented and summarized in this overview for Mirum Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIRM
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$301 Million13.79% of portfolio
-
Janus Henderson Group PLC London, X04.48MShares$205 Million0.09% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.45MShares$158 Million2.37% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$148 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$141 Million3.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.5MShares$114 Million0.0% of portfolio
-
State Street Corp Boston, MA1.79MShares$82.2 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.58MShares$72.4 Million2.1% of portfolio
-
Novo Holdings Hellerup, G71.5MShares$68.7 Million4.09% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.39MShares$63.8 Million0.01% of portfolio
Latest Institutional Activity in MIRM
Top Purchases
Top Sells
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Insider Transactions at MIRM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,489
-5.9%
|
$314,538
$42.82 P/Share
|
|
Jan 07
2025
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
1,998
-6.89%
|
$83,916
$42.82 P/Share
|
|
Jan 07
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
750
-20.4%
|
$31,500
$42.82 P/Share
|
|
Jan 06
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+25.38%
|
-
|
|
Nov 14
2024
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
2,500
-50.75%
|
$117,500
$47.1 P/Share
|
|
Nov 14
2024
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+33.67%
|
$5,000
$2.94 P/Share
|
|
Nov 08
2024
|
Joanne Quan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
118
+50.0%
|
$2,478
$21.05 P/Share
|
|
Nov 08
2024
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
65
+0.05%
|
$1,365
$21.05 P/Share
|
|
Nov 08
2024
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
475
+1.41%
|
$9,975
$21.05 P/Share
|
|
Sep 27
2024
|
Michael G Grey |
SELL
Bona fide gift
|
Indirect |
102,788
-35.54%
|
-
|
|
Sep 18
2024
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
115
+0.07%
|
$4,255
$37.4 P/Share
|
|
Sep 11
2024
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,334
+35.85%
|
-
|
|
Sep 06
2024
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
230
+0.14%
|
$9,430
$41.58 P/Share
|
|
Jul 23
2024
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
34,013
+21.15%
|
$68,026
$2.94 P/Share
|
|
Jul 02
2024
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
375
-13.39%
|
$12,750
$34.0 P/Share
|
|
Jul 01
2024
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,042
+27.11%
|
-
|
|
Jun 24
2024
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
30,559
-52.72%
|
$1,039,006
$34.0 P/Share
|
|
Jun 24
2024
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,559
+34.52%
|
$61,118
$2.94 P/Share
|
|
Jun 05
2024
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$125,000
$25.68 P/Share
|
|
Jun 05
2024
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$70,000
$14.12 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 4.35K shares |
|---|---|
| Exercise of conversion of derivative security | 94.5K shares |
| Grant, award, or other acquisition | 2.04K shares |
| Bona fide gift | 103K shares |
|---|---|
| Open market or private sale | 63.6K shares |